The purpose is to compare OAC naive patients commencing treatment with reduced dose NOAC compared to those initiating warfarin, to describe the risk of cardiovascular events including ischemic stroke/systemic embolism, intracranial hemorrhage, fatal bleeding, and other events such as kidney failure and acute kidney injury.
Lupaan tehdyt muutokset: Voimassaolon jatkaminen; Käsittelijöiden muuttaminen
Alkuperäisen luvan myöntäjä: Kela, Tilastokeskus